DaVita HealthCare Partners (DVA) saw its stock price soar by 5.05% during intraday trading on Thursday, indicating strong positive momentum.
The significant price movement appears to be driven by analyst action, as Truist Securities raised its price target on DaVita to $158 from $128, while maintaining a Hold rating. This represents a substantial increase in the firm's valuation outlook for the company.
According to analyst polls by FactSet, DaVita has an average rating of Hold with a mean price target of $151, providing additional context to the market's reaction to Truist's updated assessment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.